Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links

Expert Opinion on Investigational Drugs

Volumn 10, Issue 11, 2001, Pages 1977-1987

  Vasan, S ^a   Foiles, P G ^a   Founds, H W ^a  

^a Alteon Inc   (United States)

Author keywords

Advanced glycosylation end products; Age related diseases; ALT 711; Cross link breakers; Diabetic complications; Non enzymatic glycosylation; Pimagedine

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT INHIBITOR; ALAGEBRIUM; ALT 462; ALT 486; ALT 946; AMINE OXIDASE (COPPER CONTAINING); AMINOGUANIDINE; BENZOIC ACID DERIVATIVE; BROMINE DERIVATIVE; CARBOHYDRATE; CARBOHYDRATE DERIVATIVE; GLUCOSE; NITRIC OXIDE SYNTHASE; PEPSIN A; PHENYLTHIAZOLIUM BROMIDE; PLACEBO; STREPTOZOCIN; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

AGE; AGING; ALZHEIMER DISEASE; ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ATHEROSCLEROSIS; BRAIN INFARCTION; CARDIOVASCULAR DISEASE; CATARACT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE MODEL; DISEASE SEVERITY; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; ENZYME INDUCTION; FLU LIKE SYNDROME; GLOMERULONEPHRITIS; GLYCOSYLATION; HUMAN; HYPERGLYCEMIA; NONHUMAN; PATHOLOGY; PHYSIOLOGY; PROTEIN CROSS LINKING; PROTEIN INTERACTION; RAT; REVIEW; STREPTOZOCIN DIABETES;

ANIMALS; CLINICAL TRIALS; CROSS-LINKING REAGENTS; DIABETES COMPLICATIONS; DIABETES MELLITUS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS;

EID: 0035172601     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.11.1977     Document Type: Review

References (95)

1. Glycation and diabetic complications
2. Advanced glycosylation: Chemistry, biology, and implications for diabetes and aging
3. Advanced glycation end-products: A review
4. The pathological implications of protein glycation
5. Pharmaceutical intervention of advanced glycation endproducts. Ageing vulnerability:Causes and intervention
6. Advanced glycation end products: Detection and reversal
7. Monitoring the progress of non-enzymatic glycation in vitro
8. Immunochemical approaches to AGE-structures: Characterization of anti-AGE-antibodies
9. Advanced glycation end products induce crosslinking of collagen in vitro
10. Glycation, glycoxidation and crosslinking of collagen by glucose, kinetics, mechanism and inhibition of late stages of maillard reaction
11. Nonenzymatic glycation alters protein structure and stability: A study of two lens crystallins
12. Chronic dosing with aminoguanidine and novel advanced glycosylation end products-formation inhibitors ameliorates crosslinking of tail tendon collagen in STZ-induced diabetic rats
13. Role of maillard reaction in aging of tissue proteins. Advanced glycation end product-dependent increase in Imidazolium cross-links in human lens proteins
14. Binding and modification of proteins by methylglyoxal underphysiological conditions
15. Chemical modification of proteins by methylglyoxal
16. Protein modification by methyl glyoxal: Chemical nature and synthetic mechanism of a major fluorescent adduct
17. Protein modification by a Maillad reaction intermediate methylglyoxal. Immunochemical detection of fluorescent 5-methyllimidazolone derivatives in vivo
18. Characterization of a novel AGE-compound derived from lysine and 3-deoxyglucosone
19. Immunochemical detection of advanced glycation end products in lens crystallins from streptozotocin-induced diabetic rats
20. In vivo monitoring of serum protein crosslinking in patients with diabetes mellitus. Evidence for pharmacological modification of immunoglobulin G crosslinks
21. Immunochemical detection of advanced glycosylation end products in vivo
22. Immunochemical detection of advanced glycation end products in renal cortex from STZ-induced diabetic rat
23. Specific fluorescence assay for advanced glycation end products in blood and urine of diabetic patients
24. Immunochemical determination of advanced glycation end products in erythrocyte peripheral-membrane proteins from diabetic patients
25. Membrane proteins of human erythrocytes are modified by advanced glycation end products during aging in circulation
26. Glycation products and the pathogenesis of diabetic complications
27. Glucose and diabetic vascular disease
28. Magniude of end-stage renal disease in IDDM: A 35 year follow-up study
29. Advanced glycosylation end products in patients with diabetic nephropathy
30. Advanced glycation end products: A nephrologist's perspective
31. Ultrastructure of nonenzymatically glycated mesangial matrix in diabetic nephropathy
32. Advanced glycation end products induce glomerulosclerosis and albuminuria in normal rats
33. Immunohistochemical study of human advanced glycosylation end products (AGE) in chronic renal failure
34. Immunochemical detection of advanced glycosylation end products within vascular lesions and glomerulii in diabetic nephropathy
35. Reactive glycosylation end products in diabetic uraemia and treatment of renal failure
36. Retardation by aminoguanidine of development of albuminuria, mesangial expansion and tissue fluorescence in streptozotocin-induced diabetic rats
37. The effect of aminoguanidine on the blood-retinal barrier in streptozotocin-induced diabetic rats
38. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy
39. Immunochemical evidence for increased formation of advanced glycation end products and inhibition by aminoguanidine in diabetic rat lens
40. Role of glycation in modification of lens crystallins in diabetic and nondiabetic senile cataracts
41. Age-dependant accumulation of advanced glycosylation end products in human
42. Effects of aminoguanidine on peripheral function and polyol pathway metabolites in STZ-diabetic rats
43. Relevance of early and advanced Maillard reaction in diabetic neuropathy
44. Neurotoxicity of advanced glycation end products during focal stroke and neuroprotective effect of aminoguanidine
45. Cerebroprotective effects of aminoguanidine in a rodent model of stroke
46. Glucose - A continuous risk factor for cardiovascular disease
47. Cardiovascular regulatory mechanisms in advanced age
48. The role of glycation crosslinks in diabetic vascular stiffening
49. Effects of glucose intolerance on myocardial function and collagen-linked glycation
50. Aminoguanidine prevents diabetes-induced arterial wall protein crosslinking
51. Lipid advanced glycosylation. Pathway for lipid oxidation in vivo
52. Advanced glycosylation end products and athersclerosis
53. In vivo and in vitro evidence for the glycoxidation of low density lipoprotein in human athersclerotic plaques
54. Modification of low density lipoproteins by advanced glycosylation end products contributes to dyslipidemia of diabetes and renal insufficiency
55. CD36, a member of the class B scavenger receptor family, as a receptor for advanced glycation end products
56. Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbits
57. Immunohistochemical study of advanced glycation end products in aging and Alzheimer's disease brain
58. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases
59. Active glycation in neurofibrillary pathology of Alzheimer's disease: Ne-(Carboxymethyl)lysine and hexitol-lysine
60. Prevention of Glomerular basement membrane thickening by aminoguanidine in experimental diabetes
61. Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats
62. Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment
63. Protective effect of aminoguanidine against glomerulosclerosis in spontaneous diabetic mice
64. Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of streptozotocin-diabetic rats
65. Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology and oxygen free radicals
66. Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy
67. Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats
68. Aminoguanidine prevents decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats
69. Randomized trial of an inhibitor of advanced glycosylation end product formation in patients with diabetic nephropathy
70. Pimagedine (PG) lowers total urinary protein (TUP) and slows progression of diabetic nephropathy in patients with Type 1 Diabetes Mellitus (DM)
71. Pimagedine (PG) reduces progression of retinopathy and lowers lipid levels in patients with Type 1 diabetes mellitus (DM)
72. Pimagedine (PG) safety profile in patients with Type 1 Diabetes Mellitus (DM)
73. Aminoguanidine, a Novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction
74. Role of Endothelium-Derived Nitric Oxide in the pathogenesis of renal hemodynamic changes of experimental diabetes
75. Relative contributions of advanced glycation and nitric oxide synthase inhibition to amino-guanidine mediated renoprotection in diabetic rats
76. Biochemical effects of aminoguanidine:An update
77. N-[2-(4-morpholino)ethyl]-N′-aminoguanidine (MEAG) inhibits AGE.-formation in vitro and diabetic changes in STZ-diabetic rats without inhibiting diamine oxidase(DAO) ornitric oxide synthase (NOS)
78. Renoprotective effects of a novel inhibitor of advanced glycation
79. Novel inhibitors of advanced glycation end products
80. Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy
81. Amadorins: Novel post-Amadori inhibitors of advanced glycation reactions
82. Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end products: Comparison with aminoguanidine
83. Effects of pyridoxamine, a novel post-amadori AGE-inhibitor on nephropathy induced by glycated albumin
84. An AGE.-inhibitor, pyridoxamine(PM) is more effective than anti-oxidants or Enalapril (EP) in preventing nephropathy in STZ-diabetic rats
85. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo
86. The crosslink breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end product accumulation
87. Rapid Hydrolysis and slow α,β-dicarbonyl cleavage of an agent proposed to cleave glucose-Derived Protein Cross-links
88. Cardiovascular effects of an advanced glycation end product breaker ALT-711 in adult spontaneously hypertensive rats
89. An advanced glycation end product cross-link breaker can reverse age-related increases in myocardial stiffness
90. A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys
91. Breakers of advanced glycation end products restore large artery properties in experimental diabetes
92. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker
93. The reaction of methylglyoxal with aminoguanidine under physiological conditions and prevention of methylglyoxal binding to plasma proteins
94. Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine
95. Inhibitory effects of pyridoxal phosphate, ascorbate and aminoguanidine on non-enzymatic glycosylation